OligoChecker 2.5 released
m.winter at auckland.ac.nz
Mon Oct 18 15:54:31 EST 2004
I've just released version 2.5 of OligoChecker.
PCR has become the most used technology in biological and forensic science
during the last few years - from Ecology over Molecular Biology and Cancer
Research to Evolution. However most scientists in small labs still manage
their PCR oligos by pencil & paper.
OligoChecker was written with the small biological labs in mind - to
organise and better utilise the available oligos and thereby free scarce
funds for other projects.
Do you have a print-out of your sequence with the position of the primers
Are you using Excel to maintain a list of your oligos?
Have you just moved from working on one gene to working on a similar one and
wonder which primers you can still use for your PCR?
Do you subclone and rearrange sequences and somewhere along the line lost
track on which primer to use where?
Have you started in a new lab, inherited a box of oligos and a folder full
of printouts that came with them but no information on what they were
Have you ordered and waited for primers because you don't know which of the
ones available you can use with your sequence?
If any of these sound familiar then OligoChecker might be for you.
What's new in this version:
* Redesigned and improved user interface.
* Ability to choose two primers and run a simulated PCR.
* Output sequence of the PCR product.
* Quick manual
* Show alignment of oligo with sequence
* fixed a bug where data from the oligo list ended up in the wrong
preference list (does not change data)
* now handles non ASCII characters correctly (e.g. french characters)
* added ability to replace different versions of the same entry (e.g. you
can replace all GIBCO with GIBCO BRL in one go)
* shows total matches
* minor bug fixes
* OligoChecker is now Shareware.
* pricing ranges from $9.95 for students up to a University wide licence at
MacOS X version at:
MacOS 9 version at:
An unexpected result of ³Mac marginalisation² is that the Mac version is
released as shareware, while the Windows version will most likely be
released as a commercial product (as several companies expressed an interest
in the Windows version). On the other hand if the shareware concept for the
Mac fails then the upcoming version 3 will only be released for Windows. It
will be interesting to see how this plays out.
Dr. Markus Winter
More information about the Bioforum